Compare iShares Core MSCI Emerging Markets ETF (IEMG) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core MSCI Emerging Markets ETF vs Travere Therapeutics Inc. Common Stock — how do they compare? iShares Core MSCI Emerging Markets ETF trades at $77.15 (market cap $158.70B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: iShares Core MSCI Emerging Markets ETF is far larger — about 32.5× Travere Therapeutics Inc. Common Stock's market cap, and iShares Core MSCI Emerging Markets ETF is more actively traded (9,865,871 versus 1,668,577). Which is the better fit depends on your goals — on Pluang, investors hold iShares Core MSCI Emerging Markets ETF for 59 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| IEMG | TVTX | |
|---|---|---|
Market Cap | $158.70B | $4.88B |
Volume | 9,865,871 | 1,668,577 |
Sector | Broad Market / Factor | Health |
52-Week High | $86.00 | $67.52 |
52-Week Low | $64.72 | $26.79 |
Typical Hold Time | 59 Days | 0 Days |
Enterprise Value | — | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEMG trades at $80.22, down 0.51% with a bearish technical signal from moving averages. The ETF faces neutral oscillators but shows support at $79-80 levels. Recent news highlights IEMG's strong performance against peers like SCHE and VWO, with emerging markets attracting record inflows amid dollar weakness and tech sector exposure.
Outlook remains mixed: technical weakness contrasts with fundamental appeal via low-cost emerging market access and 35% trailing returns. Risks include concentration in tech, volatility, and expense ratio disadvantages versus competitors. Analyst sentiment leans cautious due to recent underperformance.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core MSCI Emerging Markets ETF
IEMG tracks the MSCI Emerging Markets Investable Market Index, providing broad exposure to large, mid, and small-cap stocks across over 20 emerging market countries. It is designed as a low-cost core holding for investors seeking diversified growth from economies outside of developed markets.
Read more on IEMG →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
